Moleculin Biotech (MBRX) just unveiled an announcement.
Moleculin Biotech, Inc. has released a press statement detailing recent advancements and upcoming milestones in its clinical development programs. The press release provides updates that are significant for investors and followers of the company’s progress, though the disclosed information is not intended for SEC filing purposes.
For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.
